VENOUS THROMBOEMBOLISM WITH THE USE OF ASPIRIN VERSUS ENOXAPARIN AS PROPHYLACTIC AGENTS AFTER HIP ARTHROPLASTY
Article Sidebar
Main Article Content
Abstract
Objective: To assess how often venous thromboembolism (VTE) occurs in patients on low dosage aspirin versus enoxaparin for VTE prevention after hip arthroplasty.
Methodology: This quasi-randomized controlled trial was conducted at the Department of Trauma & Orthopedics, Lady Reading Hospital, Peshawar. The study was conducted over a period of 6 months. Lottery method was used to collect data and the patients were divided into two groups. The chi-square test was used to compare the frequency of VTE between groups. Effect modifiers such as age, gender, and BMI were managed through stratification. The post-stratification chi-square test was used to determine whether there is a relationship between these impact modifiers and study results. P-value 0.05 was used to define a significant difference.
Results: A total of 74 patients undergoing total/partial hip arthroplasty in orthopedics surgery were observed, which were divided in two equal groups. Patients in Group A were managed by aspirin (75mg/day) and Group B patients received enoxaparin (0.5mg/kg). Group A had 2(5.4%) patients with VTE in follow-up and 35(94.6%) patients had observed no VTE. Group B had VTE in 4(10.8%) patients and no VTE in 33(89.2%) patients which shows that VTE was high in group B as compared to group A. The difference was insignificant with p-value=0 .337. Incidence of VTE was seen to be higher in patients aged more than 50 years.
Conclusion: The difference in incidence of VTE after hip arthroplasty with use of either Aspirin or Enoxaparin as prophylactic agents was statistically insignificant.
Article Details
Work published in JPMI is licensed under a
Creative Commons Attribution-NonCommercial 2.0 Generic License.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
References
Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Ther¬apy and Prevention of Thrombosis, 9th ed: American College of Chest Physi¬cians Evidence-Based Clinical Prac¬tice Guidelines. Chest. 2012;141(2 Suppl):e278S-e325S. DOI:10.1378/ chest.11-2404.
Berstock JR, Beswick AD, Lopez-Lopez JA, Whitehouse MR, Blom AW. Mortality After Total Knee Arthroplasty: A Sys¬tematic Review of Incidence, Temporal Trends, and Risk Factors. J Bone Joint Surg Am. 2018;100(12):1064-70. DOI:10.2106/JBJS.17.00249.
Hofstede SN, Gademan MG, Vliet Vlieland TP, Nelissen RG, Marang-van de Mheen PJ. Preoperative predictors for outcomes after total hip replacement in patients with osteoarthritis: a system¬atic review. BMC Musculoskelet Disord. 2016;17:212. DOI:10.1186/s12891- 016-1070-3.
Douketis JD. The 2016 American Col¬lege of Chest Physicians treatment guidelines for venous thromboembo¬lism: a review and critical appraisal. In¬tern Emerg Med. 2016 ;11(8):1031-35. DOI:10.1007/s11739-016-1553-0.
Afshari A, Fenger-Eriksen C, Monreal M, Verhamme P; ESA VTE Guidelines Task Force. European guidelines on perioperative venous thromboem¬bolism prophylaxis: Mechanical pro¬phylaxis. Eur J Anaesthesiol. 2018 Feb;35(2):112-115. DOI:10.1097/ EJA.0000000000000726.
Holden DN, Maceira E. Thromboembo¬lism prophylaxis failure rates after hip and knee arthroplasty: comparison of aspirin and anticoagulants. Curr Orthop Pract . 2015;26(3):277 –80.
Parvizi J, Huang R, Restrepo C, Chen AF, Austin MS, Hozack WJ, et al. Low- Dose Aspirin Is Effective Chemopro¬phylaxis Against Clinically Important Venous Thromboembolism Following Total Joint Arthroplasty: A Preliminary Analysis. J Bone Joint Surg Am. 2017 Jan 18;99(2):91-8. DOI:10.2106/ JBJS.16.00147.
Azboy I, Groff H, Goswami K, Vahedi¬an M, Parvizi J. Low-Dose Aspirin Is Adequate for Venous Thromboembo¬lism Prevention Following Total Joint Arthroplasty: A Systematic Review. J Arthroplasty. 2020 Mar;35(3):886-92. DOI:10.1016/j.arth.2019.09.043.
Matharu GS, Kunutsor SK, Judge A, Blom AW, Whitehouse MR. Clini¬cal Effectiveness and Safety of As-pirin for Venous Thromboembolism Prophylaxis After Total Hip and Knee Replacement: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med. 2020;180(3):376-84. DOI:10.1001/ jamainternmed.2019.6108.
Anderson DR, Dunbar M, Murnaghan J, Kahn SR, Gross P, Forsythe M, et al. Aspirin or rivaroxaban for VTE pro¬phylaxis after hip or knee arthroplasty. N Engl J Med. 2018;378(8):699–707. DOI:10.1056/NEJMoa1712746.
Ni Cheallaigh S, Fleming A, Dahly D, Kehoe E, O'Byrne JM, McGrath B, et al. Aspirin compared to enoxaparin or rivaroxaban for thromboprophylaxis following hip and knee replacement. Int J Clin Pharm. 2020;42(3):853-60. DOI:10.1007/s11096-020-01032-1.
Alamiri MA, Albsoul Younes AM, Al-Ajlouni JMS. Comparison between as¬pirin 325 mg and enoxaparin 40 mg as extended thromboprophylactic agents following major orthopedic surgery in Jordan University Hospital. Drugs Ther Perspect. 2019;35(1):36–42. DOI:10.1007/s40267-018-0563-6
Gelfer Y, Tavor H, Oron A, Peer A, Halp¬erin N, Robinson D. Deep vein throm¬bosis prevention in joint arthroplasties: continuous enhanced circulation ther¬apy vs low molecular weight heparin. J Arthroplasty. 2006;21(2):206–14. DOI:10.1016/j.arth.2005.04.031
Heit JA, Melton LJ 3rd, Lohse CM, Petterson TM, Silverstein MD, Mohr DN, et al. Incidence of venous throm¬boembolism in hospitalized pa¬tients vs community residents. Mayo Clin Proc. 2001;76(11):1102-10. DOI:10.4065/76.11.1102.
Wasim M, Samie A, Fawad A. Role of routine use of thromboprophylaxis in patients undergoing major surgery. Pak J Med Res. 2005;44(1):4-11.
Farey JE, An VVG, Sidhu V, Karunaratne S, Harris IA. Aspirin versus enoxapa¬rin for the initial prevention of venous thromboembolism following elec¬tive arthroplasty of the hip or knee: A systematic review and meta-anal¬ysis. Orthop Traumatol Surg Res. 2021;107(1):102606. DOI:10.1016/j. otsr.2020.04.002.
Major Extremity Trauma Research Con¬sortium (METRC); O'Toole RV, Stein DM, O'Hara NN, Frey KP, Taylor TJ, et al. As¬pirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Frac¬ture. N Engl J Med. 2023;388(3):203- 13. DOI:10.1056/NEJMoa2205973.
Flevas DA, Megaloikonomos PD, Di¬mopoulos L, Mitsiokapa E, Koulouvaris P, Mavrogenis AF. Thromboembolism prophylaxis in orthopaedics: an update. EFORT Open Rev. 2018;3(4):136-148. DOI:10.1302/2058-5241.3.170018.
Muscatelli SR, Charters MA, Hallstrom BR. Time for an Update? A Look at Current Guidelines for Venous Throm¬boembolism Prophylaxis After Hip and Knee Arthroplasty and Hip Fracture. Arthroplast Today. 2021;10:105-107. DOI:10.1016/j.artd.2021.06.015.